Lipocine is trading 5.91% down at $2.07 in pre-market on October 8, versus its October 7 close of $2.20; no confirmed new overnight company catalyst was found.
- The decline follows a volatile October 7 session after Health Canada approved TLANDO for testosterone replacement therapy, as disclosed in the company’s October 7 filing. Available reporting does not establish the approval as the reason for the drop.
- U.S. index futures are lower, but the moves are below the stated threshold for attributing Lipocine’s decline to a broad-market cause; no direct link is established.